The Stop-Loss Renewal Came in at 23 Percent. The Captive Conversation Just Got Its Trigger.

The January 2026 medical stop-loss renewal cycle finished tallying. The average annual increase came in at 23 percent — up from 18 percent the cycle before. Even the well-performing groups, the ones that had been trained to expect single-digit renewals, came in at plus 15. The stop-loss carriers issuing those numbers are calling their loss ratios unsustainable at 85 percent (against a historical 75) and are describing the next three to five years as a correction cycle, not a moment. Reinsurance treaties on the stop-loss side moved plus 15 at January 1.

This is not a hiccup. This is a market repricing itself against a different underlying claim environment than the one it was built to price.

What Is Actually Driving the Number

Two categories underneath the rate move deserve the buyer's attention.

High-cost claimants are up sharply. Individual claims exceeding one million dollars jumped nearly 30 percent in 2024 alone. Over the past four years, the same category climbed more than 60 percent. The stop-loss carrier that priced its 2020 book against a rare, ten-million-dollar tail is now pricing its 2026 book against a routine one-million-dollar working layer that used to sit just above expected. The specific attachment point is no longer specific enough.

Gene therapies and GLP-1s have entered the working claim. Gene therapy costs are running two to four million dollars per treatment. Rates for stand-alone gene therapy stop-loss products became available for 1/1/2026 renewals precisely because the standard specific-stop-loss form was never written to absorb a single approved therapy that carries a multi-million-dollar price tag. The gene therapy market is forecast to grow at a 40 percent CAGR through 2030 — meaning the claim inventory the underwriter is pricing forward is not the claim inventory the underwriter priced against a year ago. GLP-1 utilization, meanwhile, is landing inside the pharmacy pool at scale, moving the pharmacy component of the stop-loss claim curve up and to the right on almost every book.

The rate the buyer received in January is the rate the carrier is charging to hold a claim environment that has changed underneath the policy form.

What the Buyer Usually Does at This Point

The traditional broker move on a plus-23 renewal is to shop the carrier. Get three quotes. Present the lowest. Sign. The rate lands at plus 18 or 20 instead of plus 23. The buyer feels heard. The check clears. The claim environment underneath the policy has not changed.

That move works exactly once. The following January the same rate move happens again — because the same claim environment is still pricing against the same standard-market form.

The disciplined mid-market employer with three hundred lives, five hundred lives, twelve hundred lives — the segment where the plus-23 hit hardest — is running a different math this year.

The Captive Conversation as an Actual Trigger

A medical stop-loss group captive is a structure where employers with self-funded plans pool their specific and aggregate stop-loss risk with peer employers of similar size and discipline. The premium they used to send to the carrier is redirected — most of it into a captive that they collectively own, some of it into reinsurance that sits above the captive's aggregate. When the pool underperforms, the captive absorbs. When the pool outperforms, the captive returns the underwriting profit to the members. The buyer becomes the insurer of their own layer.

The captive is not the answer for every employer. Groups under 200 lives struggle to smooth their own risk. Groups without disciplined benefit administration find the captive surfaces the discipline gap they had been paying the standard market to hide. Groups that mistake the captive for a premium arbitrage usually leave in year three.

For the disciplined mid-market self-funded employer facing a plus-23 renewal, the captive is the vehicle the standard market has been chasing them toward for three years. Oliver Wyman put U.S. medical stop-loss premium volume at $35.5 billion in 2023 — up 11.9 percent from 2018 — and the captive share has grown every year of the run.

The plus-23 renewal is not the problem. The plus-23 renewal is the trigger that surfaces a problem that had been building underneath the standard form since 2020.

The Discipline Window

PFTN's captive practice is built for the buyer who wants to run the actual math — not the sales pitch. Strategic Discovery starts with the enrollment, the census, the disability rate, the pharmacy component, the specific and aggregate loss history, and the current stop-loss form (not the certificate). Risk Assessment quantifies the tier the employer is actually in — the captive-eligible tier or the not-yet tier — and names the discipline gaps that would need to close before the captive underwrites the employer, not the other way around. Solution Design pairs the captive with the right specific-stop-loss carrier, the right aggregate, the right gene-therapy carve-out, and the right pharmacy carve-in. Ongoing Optimization keeps the file current as the claim environment moves again — because it will.

The stop-loss renewal came in at 23 percent. The captive conversation just got its trigger. The runway to move on it is the twelve months in front of the next January renewal. That runway starts today.